← The Wire
CLYMNasdaq
Climb Bio, Inc.
Pharmaceutical Preparations · DE · CIK 1768446
Developing potential best-in-class therapeutics for immune-mediated diseases by targeting CD19-positive B cells
red 8-K · 90d
$655M
Market cap
$13.36
Last close
+2.1%
1D
+9.7%
5D
1.2M
Volume
Price · last 39 sessions+37.9%
May 4L $9.65 · H $13.36Jun 29
107
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KMaterial Agreement · Company UpdateJun 12, 2026424B5424B5Jun 12, 20268-KCompany UpdateJun 11, 20268-KExecutive Change · Shareholder VoteJun 8, 20268-KCompany UpdateJun 5, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 7, 20268-KReg FD DisclosureMay 5, 2026SC 13D/ASC 13D/AApr 29, 20268-KMaterial Agreement · Equity IssuanceApr 28, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 20268-KExecutive ChangeApr 3, 202610-K10-KMar 5, 20268-KResults of OperationsMar 5, 20268-KReg FD Disclosure · Company UpdateJan 8, 20268-KCompany UpdateDec 31, 2025SC 13D/ASC 13D/ADec 15, 20258-KMaterial Agreement · Equity IssuanceDec 11, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 20258-KCompany UpdateOct 17, 20258-KExecutive ChangeOct 1, 20258-KReg FD Disclosure · Company UpdateSep 29, 202510-Q10-QAug 12, 20258-KResults of OperationsAug 12, 20258-KExecutive ChangeJun 18, 20258-KShareholder VoteJun 5, 2025DEFA14ADEFA14AMay 23, 20258-KExecutive ChangeMay 23, 202510-Q10-QMay 14, 20258-KResults of OperationsMay 14, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 20258-KExecutive ChangeApr 1, 20258-KMaterial Agreement · Results of OperationsMar 25, 2025424B5424B5Mar 25, 202510-K10-KMar 25, 20258-KMaterial Agreement · Results of OperationsJan 10, 20258-KResults of Operations · Company UpdateNov 12, 202410-Q10-QNov 12, 20248-KResults of Operations · Reg FD DisclosureOct 15, 20248-KBylaw Amendment · Company UpdateOct 2, 20248-KExecutive ChangeAug 27, 20248-KExecutive ChangeAug 26, 20248-KResults of OperationsAug 14, 202410-Q10-QAug 14, 2024SC 13GSC 13GJul 2, 20248-KExecutive Change · Material AgreementJun 27, 20248-KShareholder Vote · Company UpdateJun 26, 2024DEFA14ADEFA14AJun 14, 2024DEFA14ADEFA14AJun 12, 20248-KExecutive Change · Company UpdateJun 12, 202410-Q10-QMay 15, 2024SC 13GSCHEDULE FILED TO REPORT ACQUISTION OF BENEFICIAL OWNERSHIPMay 7, 202410-K/A10-K/AApr 29, 2024DEFA14ADEFA14AApr 11, 20248-KExecutive Change · Material AgreementApr 11, 202410-K10-KMar 28, 20248-KCompany UpdateMar 19, 202410-Q10-QNov 14, 202310-Q10-QAug 10, 20238-KResults of Operations · Company UpdateJul 20, 20238-KShareholder VoteMay 19, 20238-KResults of Operations · Reg FD DisclosureMay 11, 202310-Q10-QMay 11, 2023DEFA14ADEFA14AApr 6, 2023DEF 14ADEF 14AApr 6, 20238-KExecutive ChangeMar 16, 20238-KResults of OperationsMar 6, 202310-K10-KMar 6, 20238-KExecutive Change · Results of OperationsFeb 14, 20238-KExecutive ChangeJan 24, 20238-KExecutive ChangeDec 20, 20228-KResults of Operations · Reg FD DisclosureNov 14, 202210-Q10-QNov 14, 20228-KResults of Operations · Reg FD DisclosureOct 5, 2022SC 13GSC 13GSep 22, 20228-KResults of OperationsAug 15, 202210-Q10-QAug 15, 2022
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Feb 26, 2026: 2 insiders bought $780K · 1 sold $879K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | Thomas Stephen BasilDirector | Sell | 16,313 | $7.01 | $114K |
| Feb 25, 2026 | Thomas Stephen BasilDirector | Sell | 33,687 | $7.00 | $236K |
| Feb 13, 2026 | Thomas Stephen BasilDirector | Sell | 10,000 | $5.81 | $58K |
| Feb 12, 2026 | Thomas Stephen BasilDirector | Sell | 90,000 | $5.23 | $471K |
| Jan 5, 2026 | Ra Capital Healthcare Fund LpDirector,TenPercentOwner | Buy | 7,111 | $3.50 | $25K |
| Dec 12, 2025 | Kolchinsky PeterDirector,TenPercentOwner | Buy | 101,462 | $2.86 | $290K |
| Dec 11, 2025 | Kolchinsky PeterDirector,TenPercentOwner | Buy | 213,099 | $2.18 | $465K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance